Vedolizumab does not increase perioperative surgical complications in patients with inflammatory bowel disease, cohort study
Background/Aims Biologics are increasingly used to manage ulcerative colitis (UC) and Crohn’s disease (CD). However, even with earlier usage of biologic therapy, a significant proportion of patients will require surgery. Vedolizumab is an anti-integrin antibody that is increasingly used given that i...
| Автори: | , , , |
|---|---|
| Формат: | Стаття |
| Мова: | English |
| Опубліковано: |
Korean Association for the Study of Intestinal Diseases
2022-01-01
|
| Серія: | Intestinal Research |
| Предмети: | |
| Онлайн доступ: | http://irjournal.org/upload/pdf/ir-2020-00117.pdf |